હોમ › લિમ્ફોમા › ટેક્સાસ › Houston
Houston, TX માં લિમ્ફોમા ક્લિનિકલ ટ્રાયલ્સ
Houston (લગભગ 30 માઇલની અંદર) ની સાઇટ્સ પર લિમ્ફોમા માટે 34 અભ્યાસો ભાગીદારો શોધી રહ્યા છે. કોઈ અભ્યાસ ખોલો અને જુઓ કે કોઈ જોડાઈ શકે છે અને અભ્યાસ ટીમ સાથે સંપર્ક કેવી રીતે કરવો.
અધિકૃત અભ્યાસ ટેક્સ્ટ (અંગ્રેજી)
અહીં અભ્યાસ માટે ભરતી કરી રહ્યા છો? આ પેજની ટોચ પર તેને ફીચર કરો — 30 દિવસ માટે $99 →
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
ભરતી ચાલુ છેફેઝ 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- Texas Children's Hospital, Houston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
ભરતી ચાલુ છેફેઝ 1
- The University of Texas - MD Anderson Cancer Center, Houston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
ભરતી ચાલુ છેફેઝ 2
- MD Anderson Cancer Center, Houston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
ભરતી ચાલુ છેફેઝ 1/2
- Baylor College of Medicine, Houston
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
ભરતી ચાલુ છેફેઝ 1
- University of Texas - MD Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
ભરતી ચાલુ છેફેઝ 1/2
- Research Site, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
ભરતી ચાલુ છેફેઝ 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
ભરતી ચાલુ છેફેઝ 3
- Research Site, Houston
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ભરતી ચાલુ છેફેઝ 1
- Baylor College of Medicine, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
ભરતી ચાલુ છેફેઝ 1
- The University of Texas MD Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
ભરતી ચાલુ છેફેઝ 1/2
- MD Anderson, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
ભરતી ચાલુ છેફેઝ 1/2
- MD Anderson Cancer Center, Houston
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
ભરતી ચાલુ છેફેઝ 2
- MD Anderson Cancer Center, Houston
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
ભરતી ચાલુ છેફેઝ 1
- UT MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ભરતી ચાલુ છેફેઝ 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
ભરતી ચાલુ છેફેઝ 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
ભરતી ચાલુ છેફેઝ 1
- The University of Texas M D Anderson Cancer Center, Houston
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
ભરતી ચાલુ છેફેઝ 2
- MD Anderson Cancer Center, Houston
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
ભરતી ચાલુ છેફેઝ 2
- MD Anderson Cancer Center, Houston
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
ભરતી ચાલુ છેફેઝ 2
- MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
ભરતી ચાલુ છેફેઝ 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
ભરતી ચાલુ છેફેઝ 1
- MD Anderson, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ભરતી ચાલુ છેફેઝ 1
- MD Anderson Cancer Center, Houston
CD4CAR for CD4+ Leukemia and Lymphoma
ભરતી ચાલુ છેફેઝ 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
ભરતી ચાલુ છેફેઝ 1/2
- Dren Investigational Site, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- M D Anderson Cancer Center, Houston
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
ભરતી ચાલુ છે
- MD Anderson Cancer Center, Houston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
ભરતી ચાલુ છેફેઝ 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
ભરતી ચાલુ છેફેઝ 1
- MD Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ભરતી ચાલુ છેફેઝ 2
- MD Anderson, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
ભરતી ચાલુ છેફેઝ 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
ભરતી ચાલુ છેફેઝ 1
- The University of Texas MD Anderson Cancer Center, Houston
અન્ય શહેરોમાં લિમ્ફોમા ટ્રાયલ્સ
- Boston, MA33 અભ્યાસો
- New York City, NY33 અભ્યાસો
- Washington, DC23 અભ્યાસો
- Baldwin Park, CA21 અભ્યાસો
- Chicago, IL20 અભ્યાસો
- Durham, NC17 અભ્યાસો
- St. Louis, MO15 અભ્યાસો
- Philadelphia, PA15 અભ્યાસો
- Cleveland, OH14 અભ્યાસો
- Edison, NJ12 અભ્યાસો
- Atlanta, GA12 અભ્યાસો
- Seattle, WA12 અભ્યાસો
Houston માં અન્ય અભ્યાસો
- નોન-સ્મોલ સેલ લંગ કેન્સર145 અભ્યાસો
- સ્તન કેન્સર126 અભ્યાસો
- કેન્સર (બધા પ્રકાર)121 અભ્યાસો
- મેટાસ્ટેટિક કેન્સર104 અભ્યાસો
- કોલોરેક્ટલ કેન્સર102 અભ્યાસો
- ઓવેરિયન કેન્સર89 અભ્યાસો
- એક્યુટ માયલોઇડ લ્યુકેમિયા85 અભ્યાસો
- ફેફસાનું કેન્સર78 અભ્યાસો
- પ્રોસ્ટેટ કેન્સર76 અભ્યાસો
- એન્ડોમેટ્રિયલ કેન્સર68 અભ્યાસો
- પેન્ક્રિએટિક કેન્સર61 અભ્યાસો
- મેલેનોમા59 અભ્યાસો
ClinicalTrials.gov પરથી, તારીખ 5 ઑક્ટો, 2026 ના ડેટા સાથે. દરેક અભ્યાસની પોતાની પાત્રતા શરતો હોય છે; અભ્યાસ ટીમ નક્કી કરે છે કે કોઈ જોડાઈ શકે છે કે નહીં.